TY - JOUR
T1 - Consensus Statement on Proton Therapy in Mesothelioma
AU - International Particle Therapy Cooperative Group Thoracic Subcommittee
AU - Zeng, Jing
AU - Badiyan, Shahed N.
AU - Garces, Yolanda I.
AU - Wong, Tony
AU - Zhang, Xiaodong
AU - Simone, Charles B.
AU - Chang, Joe Y.
AU - Knopf, Antje C.
AU - Mori, Shinichiro
AU - Iwata, Hiromitsu
AU - Meijers, Arturs
AU - Li, Heng
AU - Bues, Martin
AU - Liu, Wei
AU - Schild, Steven E.
AU - Rengan, Ramesh
N1 - Publisher Copyright:
© 2020 American Society for Radiation Oncology
PY - 2021/3/1
Y1 - 2021/3/1
N2 - Purpose: Radiation therapy for mesothelioma remains challenging, as normal tissue toxicity limits the amount of radiation that can be safely delivered to the pleural surfaces, especially radiation dose to the contralateral lung. The physical properties of proton therapy result in better sparing of normal tissues when treating the pleura, both in the postpneumonectomy setting and the lung-intact setting. Compared with photon radiation, there are dramatic reductions in dose to the contralateral lung, heart, liver, kidneys, and stomach. However, the tissue heterogeneity in the thorax, organ motion, and potential for changing anatomy during the treatment course all present challenges to optimal irradiation with protons. Methods: The clinical data underlying proton therapy in mesothelioma are reviewed here, including indications, advantages, and limitations. Results: The Particle Therapy Cooperative Group Thoracic Subcommittee task group provides specific guidelines for the use of proton therapy for mesothelioma. Conclusions: This consensus report can be used to guide clinical practice, insurance approval, and future research.
AB - Purpose: Radiation therapy for mesothelioma remains challenging, as normal tissue toxicity limits the amount of radiation that can be safely delivered to the pleural surfaces, especially radiation dose to the contralateral lung. The physical properties of proton therapy result in better sparing of normal tissues when treating the pleura, both in the postpneumonectomy setting and the lung-intact setting. Compared with photon radiation, there are dramatic reductions in dose to the contralateral lung, heart, liver, kidneys, and stomach. However, the tissue heterogeneity in the thorax, organ motion, and potential for changing anatomy during the treatment course all present challenges to optimal irradiation with protons. Methods: The clinical data underlying proton therapy in mesothelioma are reviewed here, including indications, advantages, and limitations. Results: The Particle Therapy Cooperative Group Thoracic Subcommittee task group provides specific guidelines for the use of proton therapy for mesothelioma. Conclusions: This consensus report can be used to guide clinical practice, insurance approval, and future research.
UR - http://www.scopus.com/inward/record.url?scp=85087512970&partnerID=8YFLogxK
U2 - 10.1016/j.prro.2020.05.004
DO - 10.1016/j.prro.2020.05.004
M3 - Review article
C2 - 32461036
AN - SCOPUS:85087512970
SN - 1879-8500
VL - 11
SP - 119
EP - 133
JO - Practical Radiation Oncology
JF - Practical Radiation Oncology
IS - 2
ER -